Astonea Labs (544409)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I’ve always said the first rule of investing is not to lose money, and the second rule is not to forget the first. Astonea Labs, at ₹158.50 with a market cap of just ₹167 Cr, makes me feel uncomfortable. Yes, sales grew 40.24%, but what good is a growing top line when profit growth is minus 33.33%? Look at the latest quarter: ₹66 Cr in sales produced only ₹1 Cr in net profit. That is a razor-thin 1.5% margin. A business that cannot convert sales into profits is not compounding my wealth; it is just consuming capital. At a P/E of 35.91, I am paying a rich price for earnings that are going backward. The PEG ratio of 0.89 looks cheap, but it is a trap because it seems to be based on sales growth, not real profit growth. Graham would demand a margin of safety; this share has none that I can measure. ROCE of 17.30% is respectable, but I cannot see book value, debt/equity, promoter holding, or a dividend. That is unacceptable for a shareholder. The Piotroski F-score of 4 out of 9 reinforces my concern about financial health. This may be an early turnaround story, but until margins improve and the balance sheet is transparent, this is not a business I can buy. I would wait, watch, and demand evidence of profitability before risking a rupee.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer